• Design Therapeutics held its annual shareholder meeting on June 9, 2026.
• Shareholders selected Simeon George, M.D. to serve as a Class II director through the 2029 annual meeting.
• Ernst & Young was ratified as independent registered public accounting firm for the fiscal year ending Dec. 31, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Design Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-267485), on June 11, 2026, and is solely responsible for the information contained therein.